HRAS and neoplasm: A significant difference in the prevalence of HRAS mutations was detected between anatomical sites (Q = 67.96, Pv <0.0001): HRAS mutations were found more frequently in tumors of the salivary glands (10.37%; 95% CI, 7.18-14.06) and oral cavity (7.36%; 95% CI, 5.39-9.76) than in tumors of the sinonasal cavity (1.2%; 95% CI, 0.2-3), oropharynx (2.6%; 95% CI, 1.12-4.56), nasopharynx (0.68%; 95% CI, 0-4.06), larynx (2.76%; 95% CI, 0.99-5.38), or hypopharynx (0.12%; 95% CI, 0-0.04).